Atherosklerose als inflammatorische Erkrankung – Pathophysiologie, klinische Relevanz und therapeutische Implikationen

Abstract

Since the early 1990 s, both experimental and clinical data have clearly demonstrated that inflammatory processes accompany atherosclerotic disease from its initiation to the development of clinical complications. Numerous biomarkers involved at various levels of the inflammation cascade have been shown to be associated with adverse cardiovascular outcomes. Among them, the classical acute phase reactant C-reactive protein (CRP) has been most intensively investigated. Recent research in this field has been driven by the observation that despite low LDL-cholesterol levels, a remarkably high number of patients are still at increased risk for recurrent cardiovascular events. This is argued to be attributable to the presence of a prolonged inflammatory response (reflected by a persistently elevated hsCRP), a concept, which is currently known as “residual inflammatory risk”. The unequivocal proof that the inflammatory process is not only a simple bystander but is also causally involved in atherogenesis, came from the recent CANTOS trial, showing a 15 % reduction of primary MACE outcomes despite aggressive statin therapy and lower LDL-cholesterol levels. Thus, an anti-inflammatory treatment strategy might represent a promising tool to improve the outcome of this still deadly disease.

Inflammatorische Vorgänge spielen eine entscheidende Rolle in allen Phasen des atherosklerotischen Prozesses. Die vorliegende Übersicht beschäftigt sich mit dem Stellenwert einer subklinischen Entzündung, diskutiert die klinische Relevanz der inflammatorischen Marker für die Risikostratifizierung und belegt die potenzielle Bedeutung einer anti-inflammatorischen Therapie für die Reduktion kardiovaskulärer Ereignisse bei Hochrisikopatienten.

Schlüsselwörter

Entzündung - Atherosklerose - C-reaktives Protein - residuales kardiovaskuläres Risiko

Key words

inflammation - atherosclerosis - C-reactive protein - residual cardiovascular risk

• Literatur

• 1 Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol 2013; 168: 5126-5134
• 2 Koenig W. Low-grade inflammation modifies cardiovascular risk even at very low LDL-C levels: are we aiming for a dual target concept?. Circulation 2018; 138: 150-153
• 3 Kaptoge S, Di Angelantonio E. Emerging Risk Factors Collaboration. et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 132-140
• 4 Sarwar N, Butterworth AS. IL6R Genetics Consortium Emerging Risk Factors Collaboration. et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012; 379: 1205-1213
• 5 Kaptoge S, Seshasai SR, Gao P. et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J 2014; 35: 578-589
• 6 Dregan A, Charlton J, Chowienczyk P. et al. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation 2014; 130: 837-844
• 7 Held C, White HD, Stewart RAH. STABILITY Investigators. et al. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc 2017; 6: pii: e005077
• 8 Ridker PM, Rifai N, Clearfield M. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-1965
• 9 Ridker PM, Cannon CP, Morrow D. et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28
• 10 Bohula EA, Giugliano RP, Cannon CP. et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation 2015; 132: 1224-1233
• 11 Ridker PM, Danielson E, Fonseca FA. JUPITER Study Group. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207
• 12 Ridker PM, Danielson E, Fonseca FA. JUPITER Trial Study Group. et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-1182
• 13 Bohula EA, Giugliano RP, Leiter LA. et al. Inflammatory and Cholesterol Risk in the FOURIER Trial. Circulation 2018; 138: 131-140
• 14 Pradhan AD, Aday AW, Rose LM. et al. Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy. Circulation 2018; 138: 141-149
• 15 Ridker PM, Everett BM, Thuren T. CANTOS Trial Group. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377: 1119-1131
• 16 Grebe A, Hoss F, Latz E. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. Circ Res 2018; 122: 1722-1740
• 17 Ridker PM, MacFadyen JG, Everett BM. CANTOS Trial Group. et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomized controlled trial. Lancet 2018; 391: 319-328
• 18 Ridker PM, Libby P, MacFadyen JG. et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J 2018; 39: 3499-3507
• 19 Deftereos S, Giannopoulos G, Papoutsidakis N. et al. Colchicine and the heart: pushing the envelope. J Am Coll Cardiol 2013; 62: 1817-1825
• 20 Crittenden DB, Lehmann RA, Schneck L. et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol 2012; 39: 1458-1464
• 21 Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol 2007; 99: 805-807
• 22 Nidorf SM, Eikelboom JW, Budgeon CA. et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013; 61: 404-410